FIGURE 1
FROM:
Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines
K Terasawa, M Toyota, S Sagae, K Ogi, H Suzuki, T Sonoda, K Akino, R Maruyama, N Nishikawa, K Imai, Y Shinomura, T Saito and T Tokino
BACK TO ARTICLEFigure 1.
Identification of TCF2 as a target for methylation in ovarian cancers. (A) Schematic diagram of the CpG island of TCF2. The chromosomal region in which TCF2 is situated is shown at the top. Vertical bars indicate CpG sites. Exon is shown by a solid box with an arrow indicating the transcription start site. The region analysed using COBRA and the position of the clone obtained with MCA are shown by respective horizontal bars. (B) Analysis of TCF2 methylation in ovarian cancer cell lines using COBRA. PCR products contain a restriction site for TaiI, which recognizes ACGT. The PCR products are digested only when the CpG sites were retained after bisulphite treatment because of methylation. The cell lines tested are shown on the top. M: methylated alleles. (C) Analysis of TCF2 methylation in primary ovarian cancer. The numbers of the cases are shown above.
